Weiguo Su

2.6k total citations
65 papers, 699 citations indexed

About

Weiguo Su is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Weiguo Su has authored 65 papers receiving a total of 699 indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Oncology, 35 papers in Pulmonary and Respiratory Medicine and 19 papers in Molecular Biology. Recurrent topics in Weiguo Su's work include Lung Cancer Treatments and Mutations (21 papers), Colorectal Cancer Treatments and Studies (14 papers) and Chronic Lymphocytic Leukemia Research (11 papers). Weiguo Su is often cited by papers focused on Lung Cancer Treatments and Mutations (21 papers), Colorectal Cancer Treatments and Studies (14 papers) and Chronic Lymphocytic Leukemia Research (11 papers). Weiguo Su collaborates with scholars based in China, United States and Australia. Weiguo Su's co-authors include Yang Sai, Yongxin Ren, Songhua Fan, Yi Gu, Weiguo Qing, Junning Cao, Jinghong Zhou, Shiming Fan, Jian Wang and Feng Zhou and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Weiguo Su

62 papers receiving 689 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Weiguo Su China	15	357	335	225	119	114	65	699
Martina Makrutzki Spain	8	500 1.4×	285 0.9×	268 1.2×	66 0.6×	128 1.1×	14	699
Oliver Boix Germany	11	499 1.4×	233 0.7×	227 1.0×	165 1.4×	88 0.8×	20	749
Lisa Rodríguez United States	12	615 1.7×	318 0.9×	287 1.3×	132 1.1×	160 1.4×	20	1.1k
Dongmei Ji China	15	539 1.5×	463 1.4×	392 1.7×	120 1.0×	196 1.7×	92	1.2k
Bogusława Karaszewska Poland	16	686 1.9×	437 1.3×	312 1.4×	53 0.4×	71 0.6×	28	976
Maja J. De Jonge Netherlands	16	449 1.3×	298 0.9×	471 2.1×	48 0.4×	91 0.8×	43	849
Hiroyuki Okabe Japan	16	584 1.6×	297 0.9×	243 1.1×	69 0.6×	145 1.3×	37	850
Sönke Korfee Germany	4	306 0.9×	273 0.8×	359 1.6×	127 1.1×	118 1.0×	8	720
Yuankai Shi China	14	547 1.5×	395 1.2×	276 1.2×	30 0.3×	184 1.6×	101	997
Osamu Tohyama Japan	6	372 1.0×	211 0.6×	259 1.2×	223 1.9×	131 1.1×	11	785

Countries citing papers authored by Weiguo Su

Since Specialization

Citations

This map shows the geographic impact of Weiguo Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weiguo Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weiguo Su more than expected).

Fields of papers citing papers by Weiguo Su

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Weiguo Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weiguo Su. The network helps show where Weiguo Su may publish in the future.

Co-authorship network of co-authors of Weiguo Su

This figure shows the co-authorship network connecting the top 25 collaborators of Weiguo Su. A scholar is included among the top collaborators of Weiguo Su based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Weiguo Su. Weiguo Su is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cheng, Ying, Panpan Zhang, Ming Lu, et al.. (2025). Efficacy and safety of surufatinib plus toripalimab in treatment-naive, PD-L1-positive, advanced or metastatic non-small-cell lung cancer and previously treated small-cell lung cancer: an open-label, single-arm, multicenter, multi-cohort phase II trial. Cancer Immunology Immunotherapy. 74(3). 83–83.

Zhang, Zheng, Yao Wu, Gang Li, et al.. (2025). Discovery of HMPL-306 (Ranosidenib), a New Potent and Selective Dual Inhibitor of Mutant IDH1 and 2 in Clinical Development for Cancer Treatment. ACS Medicinal Chemistry Letters. 16(3). 454–463. 2 indexed citations

Wang, Jie, Nong Yang, Dongqing Lv, et al.. (2025). Savolitinib (Savo) combined with osimertinib (osi) versus chemotherapy (chemo) in EGFR-mutant (EGFRm) and MET -amplification ( MET amp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI): Results from a randomized phase 3 SACHI study.. Journal of Clinical Oncology. 43(17_suppl). 3 indexed citations

Su, Weiguo, et al.. (2024). Mussel-inspired oxidized sodium alginate/cellulose composite sponge with excellent shape recovery and antibacterial properties for the efficient control of non-compressible hemorrhage. International Journal of Biological Macromolecules. 283(Pt 2). 137800–137800. 2 indexed citations

Su, Weiguo, et al.. (2024). Self-expanding cellulose sponge with enhanced hemostatic ability by tannic acid/metal ion composite coating for highly effective hemostasis of difficult-to-control bleeding wounds. Biomaterials Advances. 166. 214025–214025. 8 indexed citations

Jiang, Shuwen, et al.. (2024). Preclinical pharmacokinetic characterization of amdizalisib, a novel PI3Kδ inhibitor for the treatment of hematological malignancies. Frontiers in Pharmacology. 15. 1392209–1392209. 1 indexed citations

Wei, Xiaoting, Jialin Li, Hui Yuan, et al.. (2023). 1519P Fruquintinib plus sintilimab in patients (pts) with either treatment-naïve or previously treated advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Results from a multicenter, single-arm phase II study. Annals of Oncology. 34. S856–S856. 3 indexed citations

Xu, Jianming, Jianping Xiong, Shanzhi Gu, et al.. (2023). A phase 2 study of HMPL-453, a selective FGFR tyrosine kinase inhibitor (TKI), in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions.. Journal of Clinical Oncology. 41(16_suppl). e16118–e16118. 1 indexed citations

Wu, Zhipeng, Weigang He, Xiaoming Dai, et al.. (2023). Preclinical Pharmacology Characterization of Sovleplenib (HMPL-523), an Orally Available Syk Inhibitor. Journal of Pharmacology and Experimental Therapeutics. 388(1). 156–170. 4 indexed citations

10.

Zhou, Qing, Mengzhao Wang, Helong Zhang, et al.. (2022). Safety and Efficacy of Epitinib for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases: Open-Label Multicentre Dose-Expansion Phase Ib Study. Clinical Lung Cancer. 23(6). e353–e361. 3 indexed citations

11.

Lu, Ming, Xianjun Yu, Zewen Chen, et al.. (2021). 155P Surufatinib plus toripalimab for second-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, esophageal squamous cell carcinoma (ESCC) and neuroendocrine carcinoma (NEC): A multicenter, single-arm phase II study. Annals of Oncology. 32. S1448–S1448.

12.

Lü, Shun, Jianying Zhou, Xiaomin Niu, et al.. (2021). Fruquintinib with gefitinib as first-line therapy in patients carrying EGFR mutations with advanced non-small cell lung cancer: a single-arm, phase II study. Translational Lung Cancer Research. 10(2). 839–854. 8 indexed citations

13.

Cheng, Ying, Lin Shen, Xianjun Yu, et al.. (2021). 157P Surufatinib plus toripalimab in patients with advanced small cell lung cancer (SCLC) after failure of first-line systemic chemotherapy. Annals of Oncology. 32. S1448–S1449. 4 indexed citations

14.

Wu, Xue, Qian Chen, Tingting Li, et al.. (2020). Effects of Food on the Pharmacokinetic Properties of Surufatinib: A Phase I, Single-dose, Randomized, Open-label Crossover Study in Healthy Subjects. Clinical Therapeutics. 42(9). 1778–1786. 5 indexed citations

15.

Chen, Jiaying, Qinghai Ji, Chunmei Bai, et al.. (2020). Surufatinib in Chinese Patients with Locally Advanced or Metastatic Differentiated Thyroid Cancer and Medullary Thyroid Cancer: A Multicenter, Open-Label, Phase II Trial. Thyroid. 30(9). 1245–1253. 29 indexed citations

16.

Gan, Hui, Michael Millward, Hua Ye, et al.. (2019). First-in-Human Phase I Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Antitumor Activity. Clinical Cancer Research. 25(16). 4924–4932. 41 indexed citations

17.

Fan, Songhua, Ke Li, Yang Sai, et al.. (2019). Effects of a High-fat Meal on the Pharmacokinetics of the VEGFR Inhibitor Fruquintinib: A Randomized Phase I Study in Healthy Subjects. Clinical Therapeutics. 41(8). 1537–1544. 2 indexed citations

18.

Xu, Rui‐Hua, Jin Li, Yuxian Bai, et al.. (2017). Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. Journal of Hematology & Oncology. 10(1). 63 indexed citations

19.

Lü, Shun, Jianhua Chang, Xiaoqing Liu, et al.. (2017). OA11.03 A Randomized, Multi-Center, Double-Blind Phase II Study of Fruquintinib in Patients with Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 12(1). S286–S286. 1 indexed citations

20.

Santis, Marco De, Paweł Wiechno, Charles Lucas, et al.. (2013). Preliminary data on feasibility of vinflunine (VFL)-based combinations as 1st line in CDDP-unfit patients (pts) with advanced urothelial carcinoma (UC): VFL/gemcitabine vs. VFL/CBDCA in a randomised international phase II trial (JASINT1). European Journal of Cancer. 49. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact